Trials / Recruiting
RecruitingNCT06699420
Qishenyiqi Dripping Pill for Coronary Microvascular Disease
The Efficacy and Safety of Qishenyiqi Dripping Pill in Patients With Coronary Microvascular Disease
- Status
- Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 162 (estimated)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Qishenyiqi dripping pills 1 bag, three times a day | Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months |
| DRUG | Placebo 1 bag, three times a day | Placebo, 1 bag once, three times a day, 12 months |
Timeline
- Start date
- 2023-11-08
- Primary completion
- 2025-12-31
- Completion
- 2026-06-30
- First posted
- 2024-11-21
- Last updated
- 2024-11-21
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06699420. Inclusion in this directory is not an endorsement.